Table 2.

Distribution of monocyte subsets of PCM-p during the follow-up

ID patient	Before Treatment				During the treatment
	CD45+CD14+	CD14+CD16-	CD14+CD16+	CD14 + CD16++	CD45+CD14+	CD14+CD16-	CD14+CD16+	CD14+CD16++	Length of treatment (months)
P3	348	327	16	5	331	307	6	18	17 (ITC)
P6	933	716	158	58	221	430	16	18	20 (CMX)
P7	1164	959	118	88	776	610	4	23	20 (ITC)
P8	457	346	82	30	214	290	6	10	20 (CMX)
P9	511	350	141	20	273	360	2	15	17 (ITC)
Mean ± SEM	682.6 ± 156.0 A	539.6 ± 127.6	103.0 ± 25.2 A	40.2 ± 14.7	363.0 ± 105.4 B	399.4 ± 58.0	6.8 ± 2.4 B	16.8 ± 2.1	18.8 ± 1.4

Different letters indicate significant differences between the groups (p ≤0.05, t-paired test; A >B).

Values expressed as cell counts/μl.